Estimation of Skin Target Site Acyclovir Concentrations Following Controlled (Trans)dermal Drug Delivery in Topical and Systemic Treatment of Cutaneous HSV-1 Infections in Hairless Mice

[1]  W. Higuchi,et al.  Novel Animal Model for Evaluating Topical Efficacy of Antiviral Agents: Flux Versus Efficacy Correlations in the Acyclovir Treatment of Cutaneous Herpes Simplex Virus Type 1 (HSV-1) Infections in Hairless Mice , 1992, Pharmaceutical Research.

[2]  T. Okano,et al.  Design of 9-beta-D-arabinofuranosyladenine (ara-A) transdermal delivery system for animal studies: regulation of drug concentration in vivo. , 1991, Journal of pharmaceutical sciences.

[3]  Seung-Ho Choi,et al.  Controlled (trans) dermal delivery of an antiviral agent (acyclovir). I: An in vivo animal model for efficacy evaluation in cutaneous HSV-1 infections , 1990 .

[4]  S. Spruance,et al.  Evaluation of antiviral treatments for recurrent herpes simplex labialis in the dorsal cutaneous guinea pig model. , 1988, Antiviral research.

[5]  B. Domin,et al.  Acyclovir transport into human erythrocytes. , 1988, The Journal of biological chemistry.

[6]  S. W. Kim,et al.  Preformulation of an Ara-A transdermal delivery system: Membrane fabrication and characterization , 1987 .

[7]  A. Al-Hasani,et al.  Susceptibility of HSV strains from patients with genital herpes treated with various formulations of acyclovir. , 1986, The Journal of antimicrobial chemotherapy.

[8]  D. Smee,et al.  Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, acyclovir, and two 2'-fluoropyrimidine nucleosides. , 1985, Antiviral research.

[9]  D. A. Page,et al.  Species differences in the disposition of acyclovir. , 1982, The American journal of medicine.

[10]  C. Mclaren,et al.  Spectrum of sensitivity of acyclovir of herpes simplex virus clinical isolates. , 1982, The American journal of medicine.

[11]  G. Krueger,et al.  The histopathologic evolution of recurrent herpes simplex labialis. , 1981, Journal of the American Academy of Dermatology.

[12]  G. Flynn,et al.  Physical model evaluation of topical prodrug delivery--simultaneous transport and bioconversion of vidarabine-5'-valerate III: Permeability differences of vidarabine and n-pentanol in components of hairless mouse skin. , 1980, Journal of Pharmacy and Science.

[13]  A. Friedman-kien,et al.  Herpes Simplex Virus Skin Infection in Hairless Mice: Treatment with Antiviral Compounds , 1974, Antimicrobial Agents and Chemotherapy.

[14]  M. Lieberman,et al.  Chemotherapy of cutaneous herpesvirus infection of hairless mice. , 1973, The Journal of investigative dermatology.